Table 5.
RAPSN Methylation Differences Between LC Cases and Controls (Age<55 Years Old)
| CpG Sites | Methylation | Control (N) | Case (N) | OR (95% CI) a | p-value |
|---|---|---|---|---|---|
| RAPSN_CpG_1.15 | Q4 (≥0.95) | 57 | 51 | 1.00 (reference) | - |
| Q3 (0.94–0.95) | 30 | 14 | 0.50 (0.24–1.06) | 0.072 | |
| Q2 (0.92–0.94) | 28 | 21 | 0.85 (0.42–1.68) | 0.633 | |
| Q1 (<0.92) | 33 | 19 | 0.55 (0.27–1.12) | 0.101 | |
| RAPSN_CpG_2 | Q4 (≥0.87) | 39 | 21 | 1.00 (reference) | - |
| Q3 (0.80–0.87) | 47 | 37 | 1.47 (0.73–2.94) | 0.279 | |
| Q2 (0.77–0.80) | 28 | 25 | 1.76 (0.81–3.84) | 0.152 | |
| Q1 (<0.77) | 34 | 22 | 1.25 (0.58–2.72) | 0.569 | |
| RAPSN_CpG_3.4 | Q4 (≥0.97) | 58 | 36 | 1.00 (reference) | - |
| Q3 (0.96–0.97) | 24 | 21 | 1.48 (0.71–3.05) | 0.294 | |
| Q2 (0.94–0.96) | 42 | 25 | 1.00 (0.52–1.92) | 0.997 | |
| Q1 (<0.94) | 24 | 23 | 1.57 (0.76–3.21) | 0.220 | |
| RAPSN_CpG_5 | Q4 (≥0.98) | 39 | 30 | 1.00 (reference) | - |
| Q3 (0.96–0.98) | 51 | 27 | 0.64 (0.32–1.26) | 0.194 | |
| Q2 (0.95–0.96) | 22 | 13 | 0.77 (0.33–1.80) | 0.552 | |
| Q1 (<0.95) | 36 | 35 | 1.30 (0.66–2.55) | 0.446 | |
| RAPSN_CpG_6 | Q4 (≥0.96) | 41 | 27 | 1.00 (reference) | - |
| Q3 (0.89–0.96) | 42 | 31 | 1.10 (0.56–2.17) | 0.783 | |
| Q2 (0.84–0.89) | 29 | 28 | 1.43 (0.70–2.93) | 0.330 | |
| Q1 (<0.84) | 36 | 19 | 0.80 (0.38–1.71) | 0.571 | |
| RAPSN_CpG_7.14 | Q4 (≥0.93) | 48 | 30 | 1.00 (reference) | - |
| Q3 (0.91–0.93) | 40 | 30 | 1.20 (0.62–2.34) | 0.585 | |
| Q2 (0.89–0.91) | 42 | 18 | 0.65 (0.31–1.36) | 0.251 | |
| Q1 (<0.89) | 18 | 27 | 2.26 (1.05–4.84) | 0.036 | |
| RAPSN_CpG_8 | Q4 (≥0.99) | 47 | 42 | 1.00 (reference) | - |
| Q3 (0.97–0.99) | 48 | 31 | 0.72 (0.38–1.35) | 0.303 | |
| Q2 (0.96–0.97) | 25 | 14 | 0.61 (0.28–1.35) | 0.226 | |
| Q1 (<0.96) | 28 | 18 | 0.73 (0.35–1.54) | 0.414 | |
| RAPSN_CpG_9 | Q4 (≥0.91) | 48 | 31 | 1.00 (reference) | - |
| Q3 (0.88–0.91) | 35 | 30 | 1.36 (0.69–2.68) | 0.368 | |
| Q2 (0.85–0.88) | 36 | 23 | 0.97 (0.48–1.97) | 0.938 | |
| Q1 (<0.85) | 29 | 21 | 1.11 (0.53–2.30) | 0.785 | |
| RAPSN_CpG_10.11 | Q4 (≥0.91) | 40 | 26 | 1.00 (reference) | - |
| Q3 (0.88–0.91) | 44 | 33 | 1.25 (0.63–2.49) | 0.521 | |
| Q2 (0.85–0.88) | 33 | 28 | 1.37 (0.67–2.81) | 0.387 | |
| Q1 (<0.85) | 31 | 18 | 0.97 (0.44–2.14) | 0.947 | |
| RAPSN_CpG_12 | Q4 (≥0.94) | 46 | 41 | 1.00 (reference) | - |
| Q3 (0.92–0.94) | 38 | 30 | 0.90 (0.47–1.72) | 0.752 | |
| Q2 (0.90–0.92) | 31 | 18 | 0.70 (0.34–1.44) | 0.329 | |
| Q1 (<0.90) | 33 | 16 | 0.54 (0.26–1.14) | 0.105 |
Note: alogistic regression adjusted for age, gender and experimental batches; p< 0.05 was considered as significant difference.
Abbreviations: LC, lung cancer; N, number; OR, odd ratio; CI, confidence interval.